Significantly increased UBE2C expression level in various tumor types, including CESC, CHOL, GBM, and UCS tumors (with AUC = 100%) or in ACC, BLCA, BRCA, COAD, ESCA, KICH, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PAAD, READ, SKCM, STAD, TGCT, and UCEC tumors (with AUC ≥90%) suggest that assessing UBE2C gene expression could serve as a novel biomarker for tumor staging and a promising diagnostic tool prior to symptoms manifestation. This evidence concerns the gene UBE2C and glioblastoma.